The European Commission has launched an investigation into possible practices by the Swiss pharmaceutical company Vifor Pharma that distort competition in the market for iron pills.
Vifor Pharma has been trying to discredit its rival Pharmacosmos through misleading communication campaigns, according to indications the committee has “for years”.
According to European Commissioner Margrethe Vestager (Competition), the Swiss company, the market leader in the sale of iron pills called Ferinject, is spreading misleading information, especially among healthcare professionals, about the safety of the drug Monofer from Pharmacosmos. That Danish company also markets drugs to treat iron deficiencies.
According to Vestager, patients ultimately bear the brunt of the practices because competition distortions hinder new, innovative medicines.